Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
. These results suggest that PD-L1 on EVs may be another mechanism for glioblastoma to suppress antitumor immunity and support the potential of EVs as biomarkers in tumor patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“EVs derived from a variety of tumor types including melanoma, glioblastoma, breast, and head and neck cancer contain functional PD-L1 on their surface (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ricklefs et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“One of themost prominent molecules used by tumor cells to engage T cell immune checkpoints is programmed death ligand 1 (PD-L1) (9, 10).”
BackgroundSelf-citationSingle-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
Cited by
Items 601–632 of 632
A Microchip-Based Gauge for Visual Prediction of Immunotherapy via Distance Readout of Microvesicles
Ji, C.-X., Li, W.-W., Ding, J.-Y., Xu, Y., Xi, Y.-L., Xu, J.-Y., Lin, L.-P., Li, W., Yu, Z.-L., Jia, J., et al. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c00249
Zhang, D., Li, X., Mao, P., Guo, H., Liu, Z. W., Wang, N., Bao, G., Yu, H., & Chen, W. (2026) · Discover Oncology · doi:10.1007/s12672-026-05136-4
“Notably, the level of PD-L1 DNA in EVs derived from serum and plasma, is strong predictive factor for tumor volume [57].”
Swingle, K. L. (2026) · Springer eBooks · doi:10.1007/978-3-032-10745-9_18
Immune cell imaging in the glioma microenvironment
Wireko, A. A., Ben-Jaafar, A., Tan, J. K., Ranganathan, S., Sanker, V., Nkrumah-Boateng, P. A., Mannan, K. M., Mustapha, M. J., Gaur, A., & Broekman, M. L. D. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150394
Shi, H., Zhang, P., Wei, Q., He, H., Wu, H., Xiao, T., Liu, T., & Zeng, T. (2026) · BMC Cancer · doi:10.1186/s12885-026-16329-z
“Future research could explore combining serum PD-L1 levels with existing tumour markers (such as AFP) or using them to monitor treatment response and disease progression over time [75–79].”
Ebrahimi, F., Ezabadi, T. R., Asghari, H., Rajaeinejad, S., jalili, S., Aghamirzaei, S., Shahabinejad, E., Kouchakzade, F. S., Abbaspour, F., Lalegani, A., et al. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1705115
“MDSCs internalize EVs at rates comparable to macrophages and microglia and can also release PD-L1–loaded EVs (Ricklefs et al., 2018).”
Внеклеточные везикулы в диагностике онкологических заболеваний
Овчинникова, Л. Ю., & Ломакин, И. Э. (2025) · Acta Naturae
Ferrario, N., Fortunato, O., & Ghidotti, P. (2026) · Pharmaceuticals · doi:10.3390/ph19071023
“After this first evidence in melanoma, many other studies highlighted that PD-L1 + EVs derived from other cancer types, such as LC [129], glioblastoma [130], and prostate cancer [131], showed comparable suppressive capability against CTLs, underlining a shared immunosuppressive mechanism.”
Silva, Y. D., Chiang, D. M., Benecke, L., Pfaffl, M. W., Hayoz, S., Chiquet, S., Prince, S. S., Bettini, A., Früh, M., Mauti, L. A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1807542
“…and clinical potential has also been described and evaluated before, for example by Liu et al. (52 EVs of NSCLC patients - consistent with prior fi ndings (11, 54) - its expression levels were generally low and did not demonstrate clear prognostic or predictive signi fi cance in the overall cohort.”
Fang, J., Li, J., Yan, L., Yang, Y., Chen, Y., Zhang, X., & Zhang, C. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s596841
Tumor-intrinsic TLR4 signaling as a context-dependent rheostat in glioblastoma
Oo, T. T. (2026) · Journal of Molecular Medicine · doi:10.1007/s00109-026-02702-9
“This limited clinical benefit reflects well-documented intratumoral heterogeneity and adaptive stress responses in GBM, which enable tumor cells to survive genotoxic injury and evade immune surveillance [ 4–9 ].”
Hosseinzadeh, F., Kalhor, H., Fath‐Bayati, L., Kheirkhah, A. H., Jalise, S. Z., Yang, P., & Sheykhhasan, M. (2026) · Molecular and translational medicine · doi:10.1007/978-3-032-23810-8_9
Rewiring the Glioma Ecosystem: Glial–Tumor Crosstalk, Immune Evasion, and Therapeutic Opportunities
Oukhdouch, A., Dref, M., Nadir, Y., Bouighajd, H., Marzouka, W. A., Elbah, I., Zinbi, B., Sellami, S., Hazmiri, F. E., & Rais, H. (2026) · Neuroglia · doi:10.3390/neuroglia7030025
“EVs are also implicated in immune checkpoint regulation, as glioma-derived vesicles have been shown to transfer PD-L1 to macrophages and other immune cells, thereby intensifying local immunosuppression [137].”
Camacho, X., Ferreira, L. A. V., & Cabral, P. (2026) · SALUD MILITAR · doi:10.35954/sm2026.45.2.5.e401
Diagnostic and therapeutic applications of melanoma-derived exosomes in nanomedicine
Li, L., Zheng, X., Shi, J., Zhao, F., Chen, Y., Jia, H., Chen, J., Wang, X., Luo, P., Zhang, L., et al. (2026) · Microstructures · doi:10.20517/microstructures.2026.03
Senescence-Associated Exosomes and Intercellular Communication in Cancer
Arjmand, B., Shahrahmani, F., Moradi, S., Alavi-Moghadam, S., Rezaei–Tavirani, M., Janbabaei, G., & Rad, S. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00621-2
Targeting Multidrug Resistance in Cancer: Advances in Precision Medicine and Exosome Therapeutics
Saeed, M., Shoaib, A., Azmi, L., Arif, Y., Upadhyay, T. K., Gupta, R. C., & Aqil, F. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_20
Li, X., Su, H., Li, Y., Jiang, L., Zhou, J., Zhang, L., Huang, Y., Yang, X., & Li, M. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2713415
“…favour cell growth, suppress anti-tumour immunity through the delivery of immune checkpoint molecules such as PD-L1, which inhibit T cell function (Ricklefs et al. 2018), and disseminate inflammatory or metastasis-related factors that contribute to extracellular matrix remodelling and immune…”
Extracellular vesicles mediate immune regulation in acute kidney injury
Fu, Y.-Q., Tang, T., Chen, S.-J., Wang, B., & Liu, B.-C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1952566
“Surface proteins, including MHC class I/II, CD80/CD86, PD-L1, ICAM-1, integrins, and complement regulators (CD55, CD59), determine target-cell recognition (33, 34).”
Hsu, M. A., Hirdler, J. B., Lavoie, R. R., Orme, J. J., Hawthorne, L., Ruegg, C. L., Dodgson, J., Dong, H., Park, S. S., & Lucien, F. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s607073
Scheffel, T. B. (2025) · Directory of Open access Books (OAPEN Foundation)
Xia, L., Xue, T., Xu, Y., Yam, J. W. P., & Mao, X. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.03
Edlin Domini, T., Mathivanan, S., Paul Mathi Vathana, K., & OMAR, S. M. (2026) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2026v18i5.58481
Deng, K., & Chong, W. P. (2026) · MedComm · doi:10.1002/mco2.70983
Oluwasegun, O. H., Ogunkunle, D., Babalola, I. O., Adebisi, M., Obe, F., & Omotoso, F. I. (2026) · International Journal of Biological Research · doi:10.14419/gfrem233
Circulating sEV PD-L1: A dual biomarker and therapeutic target in cancer immune evasion
Pandiarajan, S., Kiran, V., Girigoswami, K., & Girigoswami, A. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100859
Translational Challenges and Strategies for Antibody Therapeutics in Glioblastoma
Zhou, Y., Li, Y., Chen, Y., Zhao, P., Wang, B., Zhu, H., Sun, H., Zhang, T., Zhang, A., Pan, Y., et al. (2026) · Current Oncology · doi:10.3390/curroncol33100619
“In separate co-culture experiments, PD-L1-bearing GBM EVs inhibited T-cell activation, and anti-PD-1 blockade reversed this effect when EV-associated PD-L1 was present [61].”
Zhand, S., Aboulkheyr, H., Rath, E. M., Goss, D. M., Cheng, Z., Ngai, J. S. H., Wang, Z. M., 廖佳燕, Guido, O., Lawfull, E., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.105538
Senescence and tumor immunology: A multifaceted interplay of influence
Xie, Y., Zhang, J., Wang, S., Rao, D., Zhang, J., & Ao, Y. (2026) · iScience · doi:10.1016/j.isci.2026.117849
“203 Notably, sEVs can even carry intact tumor antigens alongside PD-L1, acting as ‘‘decoys’’ that directly target CAR-T cells to inhibit their proliferation, migration, and cytotoxic function, thereby conferring resistance to CAR-T therapy.”
Oncolytic Virus‐Engineered Extracellular Vesicles Rewire Glioblastoma Immunity
Kiel, K., Balakrishnan, A., Cabaj, A., Stanaszek, L., Przybylski, M., Stępnik, D., Małuszek, M., Jannotta, C., Linke, C. Z., Suszyńska-Zajczyk, J., et al. (2026) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70389
“This pattern is consistent with an early-response, potentially antigen-independent immune state, and thus with a niche of increased resistance to efficient immune control (Neftel et al. 2019 , Ricklefs et al. 2018 , Puchalski et al. 2018 , Mineo et al. 2016 ).”
Self-citationPredictive Biomarkers to Immune Checkpoint Inhibitors in Lung Cancer
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8971-7
Fong, H. L., Leung, C. Y., Qin, T., Jiang, W., Yang, H., Ye, Y., Mengyun, P., Wang, J., Jia, B., Xu, K., et al. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2026.197
Metadata
- Authors
- Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., Rooj, A. K., Krasemann, S., Carter, B. S., Chen, C. C., Steed, T., Treiber, J., Rodig, S., Yang, K., Nakano, I., Lee, H., Weissleder, R., Breakefield, X. O., Godlewski, J., Westphal, M., Lamszus, K., Freeman, G. J., Bronisz, A., Lawler, S. E., & Chiocca, E. A.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Berkeley (US)
- Massachusetts General Hospital (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of California San Diego (US)
- Comprehensive Cancer Center, University of Birmingham, Birmingham, AL 35294, USA.
- Harvard University (US)
- Corresponding author
- Lawler, Sean E.
- Chiocca, E. Antonio
- ORCID
- Ricklefs, Franz L.
- Alayo, Quazim
- Krenzlin, Harald
- Mahmoud, Ahmad B.
- Speranza, Maria C.
- Nakashima, Hiroshi
- Hayes, Josie L.
- Lee, Kyungheon
- Balaj, Leonora
- Passaro, Carmela
- Rooj, Arun K.
- Krasemann, Susanne
- Carter, Bob S.
- Chen, Clark C.
- Steed, Tyler
- Treiber, Jeffrey
- Rodig, Scott
- Yang, Katherine
- Nakano, Ichiro
- Lee, Hakho
- Weissleder, Ralph
- Breakefield, Xandra O.
- Godlewski, Jakub
- Westphal, Manfred
- Lamszus, Katrin
- Freeman, Gordon J.
- Bronisz, Agnieszka
- Lawler, Sean E.
- Chiocca, E. Antonio
- Venue
- Science Advances
- Published
- 2018-03-02
- Volume
- 4
- Issue
- 3
- Pages
- eaar2766-eaar2766
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC5842038
- OpenAlex
- W2793992337
- Cited by
- 610
- References
- 42
- Citations by year
- 2026: 48 · 2025: 68 · 2024: 76 · 2023: 76 · 2022: 85 · 2021: 111 · 2020: 75 · 2019: 56 · 2018: 15
- FWCI
- 22.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Science Advances (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (CA176203-01A1)
- National Cancer Institute (P01 CA69246)
- Deutsche Forschungsgemeinschaft (RI 2616/1-1, RI 2616/2-1)
- National Institute of Health (NCI P01 CA69246)
- American-Italian Cancer Foundation Post-doctoral Research Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- glioblastoma, PD-L1, extracellular vesicles, immune evasion, antitumor immunity, tumor microenvironment, biomarkers
- MeSH terms
- Extracellular Vesicles, Antigens, Neoplasm, Brain Neoplasms, Glioblastoma, Humans, Interferon-gamma, Lymphocyte Activation, Receptors, Antigen, T-Cell, T-Lymphocytes, Neoplastic Stem Cells, Up-Regulation, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Immune Evasion, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.